ALAN YAGODA, M.D.; BIJAY MUKHERJI, M.D.; CHARLES YOUNG, M.D.; ERLINDA ETCUBANAS, M.D.; CHARLES LAMONTE, M.D.; JULIUS R. SMITH, M.D.; CHARLOTTE T. C. TAN, M.D.; IRWIN H. KRAKOFF, M.D., F.A.C.P.
Bleomycin, a mixture of antibiotic polypeptides, was evaluated for therapeutic activity and clinical toxicology in 274 patients with far-advanced, nonresectable neoplastic disease. Therapeutic effect was most marked in advanced Hodgkin's disease, in which 50% of patients had significant objective and subjective improvement, in some cases for periods now approaching 2 years. Scattered responses of brief duration were seen in other neoplastic diseases. The clinical toxicity of bleomycin appears to be unique among antitumor agents; it produces no important effects on the blood-forming organs, gastrointestinal tract, liver, kidneys, or central nervous system. Pulmonary functional impairment, however, is common; irreversible pulmonary fibrosis, although rare, is a serious, sometimes lethal, manifestation of bleomycin toxicity that may limit its use in early neoplastic disease.
ALAN YAGODA, BIJAY MUKHERJI, CHARLES YOUNG, ERLINDA ETCUBANAS, CHARLES LAMONTE, JULIUS R. SMITH, et al. Bleomycin, an Antitumor Antibiotic: Clinical Experience in 274 Patients. Ann Intern Med. 1972;77:861–870. doi: 10.7326/0003-4819-77-6-861
Download citation file:
Published: Ann Intern Med. 1972;77(6):861-870.
Emergency Medicine, Hematology/Oncology, Interstitial Lung Disease, Leukemia/Lymphoma, Pulmonary/Critical Care.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use